Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

This study has been completed.

Study NCT00002913 Information provided by National Cancer Institute (NCI)

First Received: November 1, 1999 Last Updated: February 6, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Publications:

Armstrong DK, Bookman MA, McGuire W, Bristow RE, Schilder JM. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 2007 Mar 16; [Epub ahead of print]

Armstrong DK, O'Reilly S, Bookman M, et al.: A phase I study of topotecan (T), cisplatin (C) and paclitaxel (P) in newly diagnosed epithelial ovarian cancer, a gynecologic oncology group (GOG 9602) study. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1351, 1998.